Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · Vaccine · Vaccine

What is yellow fever vaccine?

yellow fever vaccine is a vaccine developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesArilvax
CompanyNovartis AG
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Therapeutic Indications

yellow fever vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsYellow fever✓ Approved

Related Research Articles

PubMedAAPS PharmSciTech2026-09-19

Comprehensive Stability Assessment of Squalene in a Nanoemulsion Adjuvant and the SpiN-Tec Vaccine: HPLC Quantification, Stress Testing, and Stability Studies.

Gomes Isabela Pereira IP, Rivelli Graziella Gomes GG, Bagno Flávia Fonseca FF, Hojo-Souza Natália Satchiko NS et al.

Squalene-based nanoemulsions are widely used as adjuvants in vaccine formulations, but their stability can be affected by environmental factors such as pH, oxidative stress, temperature, and light. We have produced a squalene nanoemulsion (CTVad1) to support the clinical development of new vaccines. This study aimed to develop and validate an HPLC method for squalene quantification in SpiN-Tec, a recombinant protein vaccine against COVID-19. We also aimed to evaluate the stability of the CTVad1 adjuvant and SpiN-Tec under controlled storage conditions. A reversed-phase HPLC method was developed and validated, and comprehensive forced degradation studies were performed on the raw material and SpiN-Tec under acidic, basic, oxidative, thermal, and photolytic conditions to demonstrate the stability-indicating capability of the method. Physicochemical, morphological, and biological characteristics were assessed, and stability studies of both the vaccine and the CTVad1 adjuvant were performed under accelerated and long-term conditions. The HPLC method was selective, precise, accurate, linear, and robust. Squalene raw material degraded under all tested conditions, whereas formulation in nano-sized globules improved its stability, with degradation observed only under hydrogen peroxide and light exposure. CTVad1 remained stable over time, exhibiting only minor, non-critical changes within the specification limits in both accelerated and long-term stability studies, regardless of the glass packaging used (clear or amber). In addition, the SpiN-Tec vaccine maintained its physicochemical and biological integrity under all tested conditions, with all evaluated parameters remaining within the established specification ranges. Our findings demonstrate that proper formulation, packaging, and storage conditions can preserve squalene stability in nanoemulsion-based vaccines, ensuring the quality, safety, and efficacy of the SpiN-Tec vaccine and its adjuvant throughout shelf life.

PMID 42760453
Read full article →
PubMedOcular immunology and inflammation2026-09-19

Bilateral Maculopathy in an Infant Following Measles, Mumps, Rubella, and Varicella-Zoster (MMRV) Vaccination.

Ben-Avi Ravid R, Amer Radgonde R

To report on the long-term clinical outcome of a healthy infant who presented with posterior uveitis following the administration of the combined measles, mumps, rubella, and varicella (MMRV) vaccine. Descriptive case report. A 13-month-old infant presented with bilateral visual loss two weeks after receiving the MMRV vaccine. Ophthalmic examination revealed bilateral retinitis and retinal vasculitis with exudative retinal detachment. Extensive infectious work-up was conducted including serologic exams and PCR testing of blood, aqueous humor, cerebrospinal fluid and urine. Serological tests for measles yielded positive IgM and IgG titers. PCR testing for measles in the aqueous humor and urine was negative. Neurologic assessment and neuroimaging were unremarkable, excluding central nervous system involvement. Empiric systemic antiviral and corticosteroid therapy was initiated. Gradual resolution of posterior uveitis ensued, culminating in bilateral macular scars. Over a six-year follow-up period, the patient demonstrated stable ocular findings with no evidence of recurrent inflammation or systemic autoimmune disease. Final visual acuity was 6/9 in each eye. This case represents a rare occurrence of non-necrotizing retinitis following MMRV vaccination. To our knowledge, this is the first report describing the sequential OCT characteristics of presumed measles vaccine-associated retinitis. The prolonged follow-up period supports the absence of an alternative etiology and provides valuable insight into the long-term course and visual prognosis of vaccine-associated retinopathy.

PMID 42760840
Read full article →
PubMedMedicine2026-09-19

Symptom-based classification of Parkinson's disease using retrospective electronic medical records: A STROBE-compliant cross-sectional study.

Zhao HuiYan H, Kwon Ojin O, Jang Jae Young JY, Jeon Gyu Ri GR et al.

This cross-sectional study of electronic medical records (EMRs) was conducted to investigate symptom patterns associated with Parkinson's disease (PD) duration and severity and to explore a symptom-based classification of PD. Data from 334 patients with idiopathic PD who visited a single hospital in South Korea between 2011 and 2021, were used to extract a range of PD-associated symptoms and traditional East-Asian medicine (TEAM) symptoms. Frequency analysis was performed to identify key clinical symptoms by PD progression and severity. Patients with moderate disease severity exhibited different symptom patterns across disease-duration categories, including differences in dyskinesia, speech disorder, floating pulse, and yellow tongue coating. Hierarchical clustering based on PD-related and traditional East Asian medicine symptoms identified 5 distinct EMR-based subtypes. EMR subtype 1 was characterized by the mildest disease severity and shortest disease duration, whereas the remaining subtypes showed distinct symptom profiles and a generally greater overall symptom burden. This information may be useful for identifying clinically distinguishable EMR-based PD subtypes and symptom patterns associated with disease duration and severity. These preliminary findings provide a basis for future studies investigating whether such patterns may inform individualized approaches to PD management.

PMID 42760709
Read full article →
PubMedMedicine2026-09-19

Intractable hepatic hydrothorax eliminated by thoraco-peritoneal connection: A case report.

Lang Qing Q, Ben Xiaoyuan X, Wang Chengkang C, Zhang Jiebing J et al.

Hepatic hydrothorax occurs in patients with decompensated cirrhosis and has a significantly adverse prognosis. However, several treatments, including indwelling pleural catheters, trans jugular intrahepatic systemic shunts, and automatic low-flow ascites pumps (Alfa pumps), have been utilized to relieve pleural effusion, but these methods often cause severe complications. We report the first case of using thoraco-peritoneal connection to manage hepatic hydrothorax in a cirrhotic patient without an unfavorable outcome. A 55-year-old yellow-skinned female patient with alcoholic cirrhosis suffering from hepatic hydrothorax was admitted to the hospital. She presented with recurrent yellowish complexion, anorexia, chest tightness, and shortness of breath. The definitive diagnosis encompassed liver failure, alcoholic cirrhosis in a decompensated state, esophageal varices, portal hypertension, ascites, hepatic hydrothorax, hypersplenism, cholecystolithiasis accompanied by cholecystitis, pulmonary nodules, and coronary atherosclerosis. A thoracic drainage catheter and an abdominal puncture indwelling needle were connected to allow the pleural effusion to continuously flow into the abdominal cavity. The patient showed rapid improvement in nutritional status, urine output, and a decrease in pleural effusion. Subsequently, pleural effusion did not increase, and the connection was removed 1 month later. Hydrothorax and ascites were examined by color Doppler ultrasound every 2 months. Liver function and coagulation function continued to improve. The patient resumed normal daily activities after 6 months. The management of hepatic hydrothorax remains an area requiring further investigation. Thoraco - peritoneal connection might represent a medical strategy for the management of hepatic hydrothorax in cirrhotic patients with a favorable safety profile.

PMID 42760719
Read full article →
PubMedFrontiers in nutrition2026-09-19

Valorisation of Prosciutto di Parma PDO by-products for the development of protein-rich snacks.

Rossi Filippo F, Cassarino Martina M, Valoti Paolo P, Dall'Olio Giuliano G et al.

There is a growing demand for high-protein products from people who play sports, want to lose weight, or need to gain muscle mass. Among the most useful protein sources are meat-processed products, which, however, have a high environmental impact. The aim of the work was to create a snack rich in proteins, which allows the valorization of the residues of the slicing of raw Parma Ham a typical Italian product labeled as POD (Protected Designation of Origin), which are, currently, sold at low prices for the production of animal feed or stuffed pasta. Six different types of bars were developed, they were produced with raw ham residues (35%), pork, water, yellow corn with a high amylose content (AE), or rich in polyphenols (red or blue), pork gelatine/Psyllium fiber, flavorings. The following items were determined on the bars: centesimal composition, in vitro carbohydrate digestion, in vitro protein digestibility, polyphenols content. Statistical analysis was performed with Tukey test (p < 0.05). The composition of the bars was in this range (as fed): kcal 279 - 313; proteins 26.7%-38.1%; lipids 10.2%-12.2%; carbohydrates 14.9%-18.4%. FAO protein score (ProteinScore) on the digested fraction was greater with red corn (79 Leu) than with blue (64 Trp) and AE (64 Trp). All bars can use the claim "Rich in Protein" as defined by EFSA, the prototype AE Psyllium 5% showed the best resistant starch levels and protein score.

PMID 42760937
Read full article →
PubMedMedScience2026-09-19

Neoantigen cancer vaccines for gastrointestinal tumors: opportunities and challenges.

Zhao Zixuan Z, Du Xinyu X, Gao Xiaoliang X, Zhao Sheng S et al.

Gastrointestinal tumors are characterized by high global incidence and mortality rates. Although immune checkpoint inhibitors (ICIs) have achieved breakthroughs in some of these cancers, their overall response rate remains low. Neoantigen cancer vaccines have emerged as a promising new strategy for immunotherapy in gastrointestinal tumors due to their high specificity and strong immunogenicity. These vaccines effectively activate specific T-cell immunity and can produce synergistic effects when combined with ICIs. Various vaccine platforms offer distinct advantages, and clinical trials have shown encouraging potential in inducing immune responses and extending progression-free survival. Meanwhile, current challenges and future directions cannot be ignored. Key challenges primarily involve the accuracy of neoantigen prediction, tumor heterogeneity, and optimal treatment timing. Future directions include artificial intelligence (AI)-assisted multi-omics screening, the development of universal vaccines, optimization of novel delivery systems, and multimodal combination strategies. These advances are expected to promote the application of neoantigen cancer vaccines in postoperative recurrence prevention and early-stage treatment, ultimately moving toward personalized precision immunotherapy. This article systematically reviews the clinical progress and prospects of neoantigen cancer vaccines in treating gastrointestinal tumors, aiming to provide insights for immunotherapy in this field and offer new perspectives for further optimization of such vaccines.

PMID 42760419
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about yellow fever vaccine